Literature DB >> 10888036

Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition.

R Gussio1, D W Zaharevitz, C F McGrath, N Pattabiraman, G E Kellogg, C Schultz, A Link, C Kunick, M Leost, L Meijer, E A Sausville.   

Abstract

A congeneric series of paullones were characterized using a 3-D QSAR with cyclin-dependent kinase 1 (CDK1) inhibition data. A homology model of CDK1-cyclin B was developed from the crystal structure of CDK2-cyclin A, which subsequently served as the basis for the structure-based design. Paullones were docked into the ATP binding site of the CDK1-cylin B models and were optimized with molecular mechanics. Hydropathic analyses of the paullone-CDK1 complexes were performed after the atom types were assigned based on each ligand's electronic properties calculated from quantum mechanics. Hydropathic descriptors formed a significant multiple regression equation that predicts paullone IC50 data. The results indicate that the combination of hydropathic descriptors with molecular mechanics geometries are sufficient to design overt steric and chemical complementarity of the ligands. However, the electronic properties derived from quantum mechanics helped direct synthetic chemistry efforts to produce ligands that promote better charge transfer and strengthen hydrogen bonding as facilitated by resonance stabilization. Compounds with low affinity for CDK1 were poor charge acceptors and made less than ideal hydrogen bonding arrangements with the receptor. These considerations led to the prediction that structures such as 9-cyanopaullone would be considerably more potent than the parent compound, a finding supported by enzyme inhibition data. Also, 9-nitropaullone emerged as a paullone which also had similar potency in enzyme inhibition as well as a favorable anti-proliferative activity profile in living cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10888036

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN: 0266-9536


  5 in total

Review 1.  Selectivity and potency of cyclin-dependent kinase inhibitors.

Authors:  Jayalakshmi Sridhar; Nagaraju Akula; Nagarajan Pattabiraman
Journal:  AAPS J       Date:  2006-03-24       Impact factor: 4.009

2.  Regulation of CK2 by phosphorylation and O-GlcNAcylation revealed by semisynthesis.

Authors:  Mary Katherine Tarrant; Hee-Sool Rho; Zhi Xie; Yu Lin Jiang; Christopher Gross; Jeffrey C Culhane; Gai Yan; Jiang Qian; Yoshitaka Ichikawa; Tatsuji Matsuoka; Natasha Zachara; Felicia A Etzkorn; Gerald W Hart; Jun Seop Jeong; Seth Blackshaw; Heng Zhu; Philip A Cole
Journal:  Nat Chem Biol       Date:  2012-01-22       Impact factor: 15.040

3.  Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol.

Authors:  L T Lam; O K Pickeral; A C Peng; A Rosenwald; E M Hurt; J M Giltnane; L M Averett; H Zhao; R E Davis; M Sathyamoorthy; L M Wahl; E D Harris; J A Mikovits; A P Monks; M G Hollingshead; E A Sausville; L M Staudt
Journal:  Genome Biol       Date:  2001-09-13       Impact factor: 13.583

4.  Unprecedented nucleophile-promoted 1,7-S or Se shift reactions under Pummerer reaction conditions of 4-alkenyl-3-sulfinylmethylpyrroles.

Authors:  Takashi Go; Akane Morimatsu; Hiroaki Wasada; Genzoh Tanabe; Osamu Muraoka; Yoshiharu Sawada; Mitsuhiro Yoshimatsu
Journal:  Beilstein J Org Chem       Date:  2018-10-29       Impact factor: 2.883

5.  Antitumor activity of cyclin-dependent kinase inhibitor alsterpaullone in Epstein-Barr virus-associated lymphoproliferative disorders.

Authors:  Takahiro Watanabe; Yoshitaka Sato; H M Abdullah Al Masud; Masahiro Takayama; Hiroki Matsuda; Yuya Hara; Yusuke Yanagi; Masahiro Yoshida; Fumi Goshima; Takayuki Murata; Hiroshi Kimura
Journal:  Cancer Sci       Date:  2019-12-11       Impact factor: 6.716

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.